Sugi Predict

Sugi Predict / Compounds / SCHEMBL1384473

SCHEMBL1384473

SCHEMBL1384473

COCOc1ccc(C(=O)Cn2c(-c3nonc3N)nc3ccccc32)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.61
▸ HCRTR1 O43613 1/20 0.61
▸ HCRTR2 O43614 1/20 0.61
▸ HTT P42858 1/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.61
▸ KDM4E B2RXH2 1/20 0.57
▸ BCHE P06276 4/20 0.57
▸ TP53 P04637 1/20 0.57
▸ SMN1; SMN2 Q16637 1/20 0.57
▸ LMNA P02545 2/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ ALOX15 P16050 1/20 0.53
▸ NPY1R P25929 1/20 0.53
▸ NPY2R P49146 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2584080 0.90 TSHR (0.61) TSHRHCRTR1HCRTR2HTTNPSR1
SCHEMBL2582378 0.88 KDM4E (0.61) TSHRHCRTR1HCRTR2HTTNPSR1
SCHEMBL1386316 0.83 BCHE (0.68) TSHRKDM4EBCHETP53SMN1; SMN2
SCHEMBL1385703 0.82 TSHR (0.68) TSHRKDM4EBCHETP53SMN1; SMN2
SCHEMBL11890502 0.80 KDM4E (0.73) TSHRKDM4EBCHETP53SMN1; SMN2
SCHEMBL1387066 0.79 KDM4E (0.80) TSHRHTTKDM4ELMNA
SCHEMBL2579670 0.78 KDM4E (0.66) TSHRKDM4EBCHETP53
SCHEMBL1906791 0.78 BCHE (0.77) TSHRHCRTR1HCRTR2HTTNPSR1
SCHEMBL2581813 0.78 KDM4E (0.68) TSHRKDM4EBCHETP53SMN1; SMN2
SCHEMBL1386481 0.78 KDM4E (0.71) TSHRKDM4EBCHETP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4829791-B2 — — 2011-12-07 — — JP claimed
EP-1636215-B1 FURAZANOBENZIMIDAZOLES BASILEA PHARMACEUTICA AG (CH) 2008-01-23 — — EP claimed
US-20070043061-A1 Furazanobenzimidazoles BASILEA PHARMACEUTICA AG 2007-02-22 — — US claimed
JP-2006528238-A — — 2006-12-14 — — JP claimed
EP-1636215-A1 FURAZANOBENZIMIDAZOLES Basilea Pharmaceutica AG (CH) 2006-03-22 — — EP claimed
WO-2004103994-A1 FURAZANOBENZIMIDAZOLES BASILEA PHARMACEUTICA AG (CH) 2004-12-02 — — WO claimed
US-10724072-B2 Use of phospho-Akt as a biomarker of drug response BASILEA PHARMACEUTICA AG (CH) 2020-07-28 — — US disclosed
US-10656162-B2 Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles BASILEA PHARMACEUTICA AG (CH) 2020-05-19 — — US disclosed
US-10222377-B2 Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles BASILEA PHARMACEUTICA AG (CH) 2019-03-05 — — US disclosed
US-20190010536-A1 USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE BASILEA PHARMACEUTICA AG (CH) 2019-01-10 — — US disclosed
US-20180364254-A1 USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES BASILEA PHARMACEUTICA AG 2018-12-20 — — US disclosed
US-10067120-B2 Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles BASILEA PHARMACEUTICA AG (CH) 2018-09-04 — — US disclosed
US-10006078-B2 Use of phospho-Akt as a biomarker of drug response BASILEA PHARMACEUTICA AG (CH) 2018-06-26 — — US disclosed
WO-2012098203-A1 USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES BASILEA PHARMACEUTICA AG (CH) 2012-07-26 — — WO disclosed
US-RE42890-E1 Furazanobenzimidazoles BASILEA PHARMACEUTICA AG (CH) 2011-11-01 — — US disclosed
US-7385061-B2 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-yl]-N-(2-cyanoethyl)-amine; treatment of neoplastic and autoimmune diseases BASILEA PHARMACEUTICA AG (CH) 2008-06-10 — — US disclosed
EP-1636215-B1 FURAZANOBENZIMIDAZOLES BASILEA PHARMACEUTICA AG (CH) 2008-01-23 — — EP disclosed
US-20070043061-A1 Furazanobenzimidazoles BASILEA PHARMACEUTICA AG 2007-02-22 — — US disclosed
EP-1636215-A1 FURAZANOBENZIMIDAZOLES Basilea Pharmaceutica AG (CH) 2006-03-22 — — EP disclosed
WO-2004103994-A1 FURAZANOBENZIMIDAZOLES BASILEA PHARMACEUTICA AG (CH) 2004-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10724072-B2 Use of phospho-Akt as a biomarker of drug response AKT3, AKT1S1, AKT2 TSHR 818/4885HCRTR1 3819/4885HCRTR2 2792/4885
US-10656162-B2 Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles TUBB, TUBB1, TUBB6 TSHR 4340/4885HCRTR1 4330/4885HCRTR2 4402/4885
US-20180364254-A1 USE OF GLU-TUBULIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES TUBB, TUBB1, TUBB6 TSHR 4340/4885HCRTR1 4330/4885HCRTR2 4402/4885
US-20190010536-A1 USE OF PHOSPHO-AKT AS A BIOMARKER OF DRUG RESPONSE AKT3, AKT1S1, AKT2 TSHR 818/4885HCRTR1 3819/4885HCRTR2 2792/4885
US-10067120-B2 Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles TUBB1, TUBB, TUBB6 TSHR 4281/4885HCRTR1 3986/4885HCRTR2 4149/4885
US-10222377-B2 Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles BUB1B, BUB1, BUB3 TSHR 2717/4885HCRTR1 1146/4885HCRTR2 2489/4885
US-10006078-B2 Use of phospho-Akt as a biomarker of drug response AKT3, AKT2, AKT1S1 TSHR 3124/4885HCRTR1 4310/4885HCRTR2 4032/4885
US-20070043061-A1 Furazanobenzimidazoles FOXO1, CYP2F1, OXER1 TSHR 1025/4885HCRTR1 1069/4885HCRTR2 1443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.